Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2327144 | 1.00 | KMT2A (0.66) | KMT2ARAB9AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL2323670 | 0.90 | KMT2A (0.56) | KMT2ARAB9AL3MBTL1FNTAFNTB | |
| SCHEMBL2326551 | 0.90 | KMT2A (0.66) | KMT2ARAB9AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL2326548 | 0.90 | KMT2A (0.66) | KMT2ARAB9AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL3857432 | 0.88 | KMT2A (0.54) | KMT2ARAB9AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL2324014 | 0.88 | RAB9A (0.53) | KMT2ARAB9AL3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL2324006 | 0.88 | RAB9A (0.53) | KMT2ARAB9AL3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL2328058 | 0.86 | KMT2A (0.62) | KMT2ARAB9AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL2328054 | 0.86 | KMT2A (0.62) | KMT2ARAB9AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL2327402 | 0.86 | ALDH1A1 (0.53) | KMT2AALDH1A1NPSR1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356979-B1 | ANTI-WRINKLE AGENTS | POLA CHEM IND INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-3173063-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2017-05-31 | — | — | EP | disclosed |
| US-8835498-B2 | Anti-wrinkle agents | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-2356979-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | GLA, H1-4, H1-3 | KMT2A 3153/4885RAB9A 4160/4885L3MBTL1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.